Thompson Siegel & Walmsley LLC Sells 52,621 Shares of Laboratory Co. of America Holdings (NYSE:LH)

Thompson Siegel & Walmsley LLC trimmed its position in shares of Laboratory Co. of America Holdings (NYSE:LH - Free Report) by 17.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 249,392 shares of the medical research company's stock after selling 52,621 shares during the period. Thompson Siegel & Walmsley LLC owned about 0.29% of Laboratory Co. of America worth $56,685,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Morgan Stanley grew its position in shares of Laboratory Co. of America by 102.6% during the third quarter. Morgan Stanley now owns 2,219,291 shares of the medical research company's stock worth $446,189,000 after acquiring an additional 1,123,755 shares during the last quarter. Diamond Hill Capital Management Inc. lifted its holdings in shares of Laboratory Co. of America by 644.2% during the third quarter. Diamond Hill Capital Management Inc. now owns 1,280,884 shares of the medical research company's stock worth $257,522,000 after purchasing an additional 1,108,776 shares during the period. Allspring Global Investments Holdings LLC lifted its holdings in shares of Laboratory Co. of America by 3,836.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 806,975 shares of the medical research company's stock worth $162,243,000 after purchasing an additional 786,477 shares during the period. Lazard Asset Management LLC lifted its holdings in shares of Laboratory Co. of America by 28.0% during the third quarter. Lazard Asset Management LLC now owns 2,212,497 shares of the medical research company's stock worth $444,821,000 after purchasing an additional 483,878 shares during the period. Finally, Ameriprise Financial Inc. lifted its holdings in shares of Laboratory Co. of America by 536.0% during the third quarter. Ameriprise Financial Inc. now owns 540,429 shares of the medical research company's stock worth $108,653,000 after purchasing an additional 455,462 shares during the period. 95.94% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on LH. Truist Financial decreased their price target on Laboratory Co. of America from $270.00 to $255.00 and set a "buy" rating for the company in a report on Friday, April 26th. Leerink Partnrs reaffirmed an "outperform" rating on shares of Laboratory Co. of America in a report on Monday, February 26th. TheStreet downgraded Laboratory Co. of America from a "b-" rating to a "c+" rating in a report on Thursday, February 15th. SVB Leerink initiated coverage on Laboratory Co. of America in a report on Monday, February 26th. They set an "outperform" rating and a $260.00 price target for the company. Finally, Barclays decreased their target price on shares of Laboratory Co. of America from $234.00 to $213.00 and set an "equal weight" rating on the stock in a research report on Friday, April 26th. Four analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $243.14.

Insider Transactions at Laboratory Co. of America

In related news, CAO Peter J. Wilkinson sold 2,439 shares of the firm's stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $204.33, for a total transaction of $498,360.87. Following the sale, the chief accounting officer now owns 2,087 shares in the company, valued at $426,436.71. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other Laboratory Co. of America news, CFO Glenn A. Eisenberg sold 34,504 shares of Laboratory Co. of America stock in a transaction on Wednesday, February 21st. The shares were sold at an average price of $215.97, for a total value of $7,451,828.88. Following the transaction, the chief financial officer now owns 23,595 shares in the company, valued at approximately $5,095,812.15. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CAO Peter J. Wilkinson sold 2,439 shares of Laboratory Co. of America stock in a transaction on Monday, April 29th. The shares were sold at an average price of $204.33, for a total transaction of $498,360.87. Following the completion of the transaction, the chief accounting officer now owns 2,087 shares in the company, valued at approximately $426,436.71. The disclosure for this sale can be found here. Insiders sold a total of 56,985 shares of company stock valued at $12,302,964 in the last ninety days. Corporate insiders own 0.85% of the company's stock.

Laboratory Co. of America Price Performance

Shares of LH traded up $1.52 during mid-day trading on Friday, reaching $207.67. 722,931 shares of the company's stock were exchanged, compared to its average volume of 838,174. The company has a quick ratio of 0.76, a current ratio of 0.88 and a debt-to-equity ratio of 0.39. The company has a 50-day simple moving average of $208.89 and a two-hundred day simple moving average of $214.81. Laboratory Co. of America Holdings has a 52-week low of $174.20 and a 52-week high of $234.09. The company has a market cap of $17.51 billion, a price-to-earnings ratio of 41.78, a PEG ratio of 1.55 and a beta of 1.02.

Laboratory Co. of America (NYSE:LH - Get Free Report) last issued its quarterly earnings data on Thursday, April 25th. The medical research company reported $3.68 earnings per share for the quarter, topping analysts' consensus estimates of $3.48 by $0.20. Laboratory Co. of America had a net margin of 3.52% and a return on equity of 14.68%. The business had revenue of $3.18 billion during the quarter, compared to analysts' expectations of $3.12 billion. During the same period last year, the company posted $3.82 EPS. The company's revenue was up 4.6% on a year-over-year basis. On average, sell-side analysts predict that Laboratory Co. of America Holdings will post 14.87 EPS for the current fiscal year.

Laboratory Co. of America Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 12th. Stockholders of record on Tuesday, May 28th will be paid a dividend of $0.72 per share. The ex-dividend date is Friday, May 24th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.39%. Laboratory Co. of America's dividend payout ratio (DPR) is 57.95%.

Laboratory Co. of America Profile

Laboratory Corporation of America Holdings operates as a life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Biopharma Laboratory Services (BLS).